Phreesia (NYSE:PHR) Given “Buy” Rating at Canaccord Genuity Group

Phreesia (NYSE:PHR)‘s stock had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group in a report released on Thursday, Benzinga reports. They presently have a $16.00 price target on the stock. Canaccord Genuity Group’s price target would indicate a potential upside of 34.68% from the stock’s previous close.

A number of other research analysts have also recently weighed in on PHR. Wells Fargo & Company set a $10.00 price objective on shares of Phreesia in a research report on Thursday. Piper Sandler lowered shares of Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 target price for the company. in a report on Thursday, May 28th. Wall Street Zen raised shares of Phreesia from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Weiss Ratings upgraded shares of Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Finally, Barclays reissued an “equal weight” rating and issued a $10.00 price objective (down from $24.00) on shares of Phreesia in a research report on Thursday, May 14th. Nine equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $16.71.

Phreesia Stock Up 0.3%

Shares of NYSE:PHR opened at $11.88 on Thursday. The company has a market cap of $734.30 million, a price-to-earnings ratio of 79.20 and a beta of 0.86. Phreesia has a 12 month low of $7.77 and a 12 month high of $31.83. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $11.19 and a 200 day moving average price of $10.48.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Wednesday, September 2nd. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.06). Phreesia had a return on equity of 5.13% and a net margin of 1.85%.The company had revenue of $129.46 million for the quarter, compared to the consensus estimate of $129.06 million. During the same period in the previous year, the firm earned $0.01 earnings per share. The company’s revenue was up 10.4% compared to the same quarter last year. As a group, equities research analysts predict that Phreesia will post 0.39 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after buying an additional 16,309 shares during the period. AQR Capital Management LLC lifted its holdings in Phreesia by 471.2% in the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock valued at $4,090,000 after acquiring an additional 132,015 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Phreesia by 3.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after purchasing an additional 2,158 shares in the last quarter. NewEdge Advisors LLC grew its stake in shares of Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after purchasing an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after purchasing an additional 2,402 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Management maintained fiscal 2027 revenue guidance of $510 million to $520 million, broadly in line with Wall Street expectations, reducing the risk of a near-term outlook cut. Phreesia maintains FY2027 revenue outlook
• Positive Sentiment: Phreesia reported positive operating and free cash flow for the quarter and reduced debt principal by more than $23 million, supporting balance-sheet improvement and potentially lowering future interest costs. Phreesia Announces Second Quarter Fiscal 2027 Results
• Positive Sentiment: Management identified AccessOne as a multi-year growth opportunity, giving investors an additional potential driver beyond the company’s core revenue expansion. Needham & Company also initiated or reiterated a Buy rating, adding analyst support. Needham Buy Rating
• Neutral Sentiment: The quarter’s revenue growth and profitability expansion were described as in line with expectations, suggesting execution remains steady but did not produce a major upside surprise. Phreesia Q2 2027 Earnings Call Transcript
• Negative Sentiment: Adjusted earnings were materially below consensus at $0.03 per share versus the expected $0.09-$0.11. The miss may limit upside for PHR despite the revenue beat and maintained full-year outlook. Phreesia Q2 Earnings and Revenues Lag Estimates

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.